The company will use the money to fund clinical trials and develop a marketing operation.
January 19, 2018 -- Ascletis, a Hangzhou company developing a oral interferon-free combination treatment for hepatitis C, is planning a $100 million C funding. The company will use the money to fund clinical trials and develop a marketing operation. Previously, Ascletis raised $155 million in two rounds of venture capital, plus another $100 million in startup investment. After the C Round, Ascletis is considering an IPO in Hong Kong, the exchange of choice for young China biopharmas now that it no longer requires several years of profitable operations before listing.
